Analysts Are Bullish on These Healthcare Stocks: EPZM, BGNE

By Austin Angelo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Epizyme (NASDAQ: EPZM) and BeiGene Ltd (NASDAQ: BGNE) with bullish sentiments.

Epizyme (NASDAQ: EPZM)

Cowen & Co. analyst Phil Nadeau reiterated a Buy rating on Epizyme (NASDAQ: EPZM) today. The company’s shares opened today at $12.

According to TipRanks.com, Nadeau is a 3-star analyst with an average return of 2.0% and a 43.5% success rate. Nadeau covers the Healthcare sector, focusing on stocks such as Achillion Pharmaceuticals, Catabasis Pharmaceuticals, and Voyager Therapeutics Inc.

Currently, the analyst consensus on Epizyme is Strong Buy and the average price target is $23, representing a 91.7% upside.

In a report issued on June 5, Oppenheimer also reiterated a Buy rating on the stock with a $26 price target.
BeiGene Ltd (NASDAQ: BGNE)

In a report released today, Eric Schmidt from Cowen & Co. reiterated a Buy rating on BeiGene Ltd (NASDAQ: BGNE). The company’s shares opened today at $39.39, close to its 52-week high of $42.28.

Schmidt commented:

“Abstracts from ICML further support BGB-3111’s efficacy profile as being superior.”

According to TipRanks.com, Schmidt is a top 100 analyst with an average return of 25.8% and a 54.3% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.

Currently, the analyst consensus on BeiGene Ltd is Moderate Buy and the average price target is $52, representing a 32.0% upside.

In a report issued on June 5, Maxim Group also reiterated a Buy rating on the stock with a $52 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.